<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In this study we investigated telomere restriction fragment (TRF) length in a panel of mature B-cell <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> (MBCLDs) and correlated this parameter with histology and histopathogenesis in relation to the germinal center (GC) </plain></SENT>
<SENT sid="1" pm="."><plain>We assessed 123 MBCLD samples containing 80% or more <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="2" pm="."><plain>TRF length was evaluated by Southern blot analysis using a chemiluminescence-based assay </plain></SENT>
<SENT sid="3" pm="."><plain>GC status was assessed through screening for stable and ongoing <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> within the immunoglobulin heavy-chain genes </plain></SENT>
<SENT sid="4" pm="."><plain>Median TRF length was 6170 bp (range, 1896-11 200 bp) and did not correlate with patient age or sex </plain></SENT>
<SENT sid="5" pm="."><plain>TRF length was greater in diffuse large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (medians: 7789 bp, 9471 bp, and 7383 bp, respectively) than in mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (medians: 3582 bp and 4346 bp, respectively) </plain></SENT>
<SENT sid="6" pm="."><plain>GC-derived MBCLDs had the longest telomeres, whereas those arising from GC-inexperienced cells had the shortest (P &lt; 10(-9)) </plain></SENT>
<SENT sid="7" pm="."><plain>We conclude that (1) TRF length in MBCLD is highly <z:hpo ids='HP_0001425'>heterogeneous</z:hpo>; (2) GC-derived <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> have long telomeres, suggesting that minimal telomere <z:mpath ids='MPATH_580'>erosion</z:mpath> occurs during GC-derived <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e>; and (3) the short TRF lengths of GC-inexperienced MBCLDs indicates that these <z:hpo ids='HP_0002664'>neoplasms</z:hpo> are good candidates for treatment with telomerase inhibitors, a class of molecules currently the subject of extensive preclinical evaluation </plain></SENT>
</text></document>